Fifer, Simon
Rose, John
Hamrosi, Kim K.
Swain, Dan
Funding for this research was provided by:
AstraZeneca Australia
Article History
Received: 16 April 2018
Accepted: 20 August 2018
First Online: 30 August 2018
Ethics approval and consent to participate
: Ethics: The study was conducted under the Australian Market and Social Research Society (AMSRS) Code of Professional Behaviour which covered the ethical requirements and standard conditions of conducting and reporting market and social research.Patient involvement and consent: The development of the research question and design of the study is based on the creating real life treatment decisions patients pay face when selecting between treatments. The content and associated attributes used in the DCE study was informed by initial qualitative research with patients and a review of patient literature, however no direct patient input was used in finalising the included attributes. This information provided context to the study to firstly better understand patient’ priorities, experiences and preferences for treatment with type 2 diabetes and secondly ensure that the relevant attributes of treatment were included in the DCE. A pilot was conducted with patients and feedback received. Revisions were consequently made to the study design and content. All patients were asked to provide consent to participate by selecting an option in the online survey.To be able to ensure the results of the study are available to anyone, particularly patients, who are interested in knowing more about preferences for treatment of type 2 diabetes we are electing to submit to a journal with open access.
: Not applicable.
: DS was an employee of AstraZeneca at the time of the study.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.